UroGen Pharma Ltd.

URGN - CIK 0001668243

Market cap$1.37 B

Rank#2404

SEC filings549

UroGen Pharma Ltd. trades as URGN and has a market capitalization of $1.37 B, making it the #2404 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $109.79M, up 21.4% from the prior year and net income of -$153.49M. This page tracks UroGen Pharma Ltd. through 549 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$109.79MFY 2025

Net income (latest FY)-$153.49MFY 2025

Operating cash flow (latest FY)-$162.44MFY 2025

Total assets (latest FY)$200.46MFY 2025

Gross margin88.7%latest FY

Net margin-139.8%latest FY

Financial performance

Over the last 9 fiscal years UroGen Pharma Ltd.'s revenue grew from $17.53M to $109.79M, a compound annual growth rate of 22.6%. Net profit margin compressed from -11.1% to -139.8% over the same period - every figure below comes from the company's audited annual filings.

URGN annual revenueView details

Key statistics

Market cap: $1.37 B
Share price (derived)market cap / shares outstanding: $28.14
Shares outstandingas of 2026-05-01: 0.05B
Total equityas of 2024-09-30: $25.52M
Return on equity: -601.6%
Long-term debtas of 2026-03-31: $200.00M
Cash & equivalentsas of 2026-03-31: $109.97M
Current ratioas of 2026-03-31: 4.69

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-27
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G	-	2026-05-15
Insider trade	4	2026-05-11
Insider sale notice	144	2026-05-08
Quarterly report	10-Q	2026-05-06
Major company event	8-K	2026-05-06
Proxy statement	DEF 14A	2026-04-30

Browse the full filing history (549 filings)

Recent press releases

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution2026-06-02
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution | UroGen Pharma, Ltd
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference2026-06-01
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | UroGen Pharma, Ltd
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC2026-05-15
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC | UroGen Pharma, Ltd
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial2026-05-13
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial | UroGen Pharma, Ltd
UroGen Pharma to Present at Upcoming Investor Conferences2026-05-07
UroGen Pharma to Present at Upcoming Investor Conferences | UroGen Pharma, Ltd

Similar companies

The largest companies sharing UroGen Pharma Ltd.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T URGN vs LLY

JNJJohnson & Johnson$573.98 B URGN vs JNJ

ABBVAbbVie Inc.$399.47 B URGN vs ABBV

MRKMerck & Co., Inc.$293.16 B URGN vs MRK

AZNAstraZeneca PLC$286.27 B URGN vs AZN

Frequently asked questions

What is UroGen Pharma Ltd.'s market cap?

UroGen Pharma Ltd. (URGN) has a market capitalization of $1.37 B as of 2026-06-10, ranking #2404 among US-listed companies.

How much revenue does UroGen Pharma Ltd. make?

UroGen Pharma Ltd. reported revenue of $109.79M for fiscal year 2025, an increase of 21.4% year over year.

Is UroGen Pharma Ltd. profitable?

In its latest fiscal year UroGen Pharma Ltd. reported a net loss of $153.49M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.